Autologous IL-12/Multi-targeted Primed T-cells RPTR 168

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of genetically modified, multi-antigen-targeted autologous T-lymphocytes, tethered with the human immunostimulatory cytokine interleukin-12 (IL-12), with potential immunostimulating and antineoplastic activities. RPTR 168 is prepared from monocyte-derived dendritic cells (moDCs) that are pulsed with five tumor-associated antigens (TAAs) to expand cytotoxic T-lymphocytes (CTLs) that are subsequently loaded with IL-12. Upon administration, the autologous IL-12/multi-targeted primed T-cells RPTR 168 specifically target tumor cells expressing the five TAAs, which lead to a specific cytotoxic T-lymphocyte (CTL)-mediated killing of these tumor cells. In addition, IL-12 expression activates the immune system by promoting the secretion of interferon-gamma (IFN-g), activating natural killer cells (NKs), and inducing CTL responses, which may further increase tumor cell death and decrease tumor cell proliferation.

**Synonyms:** - Autologous IL-12-expressing MTC RPTR 168 - Autologous IL-12/Multi-targeted Primed T-lymphocytes RPTR 168 - PRIME IL-12 - RPTR 168 - RPTR-168 - RPTR168